Prof M Baum (Chairman and Principal Investigator for the main ATAC trial), University College London, London, UK; Prof AR Bianco, Universita Degli Studi Di Napoli Federico II, Napoli, Italy; Dr A Buzdar, The University of Texas, M.D. Anderson Cancer Centre, Houston, TX, USA; Dr M Coibion, Institut Bordet, Bruxelles, Belgium; Prof Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield, UK; Dr M Constenla, Hospital Montecelo, Pontevedra, Spain; *Prof J Cuzick (independent statistician), Cancer Research UK, London, UK; Prof Dr W Distler, Universitdtsklinikum Carl Gustav Carus Dresden, Dresden, Germany; Prof M Dowsett, The Royal Marsden Hospital, London, UK; Prof J Forbes, Newcastle Mater Misericordiae Hospital, New South Wales, Australia; Prof WD George, Beatson Oncology Centre, Western Infirmary, Glasgow, UK; J Gray, Belfast City Hospital, Belfast, UK; Dr JP Guastalla, Centre Leon Berard, Lyon, France; J Houghton, Dr N Williams, Clinical Trials Group of the Department of Surgery, UCL, London, UK, *Prof A Howell, Christie Hospital, Manchester, UK; Prof Dr JGM Klijn, Dr Daniel den Hoed Kliniek, University Hospital Rotterdam, Rotterdam, The Netherlands; *Dr GY Locker, Evanston Hospital, Kellogg Cancer Care Center, Evanston IL, USA; Dr John Mackey, Cross Cancer Institute, Edmonton, Canada; Prof RE Mansel, University of Wales College of Medicine, Cardiff, UK; Dr JM Nabholtz, University of California at Los Angeles, Los Angeles, CA, USA; Dr T Nagykalnai, Uzsoki U Hospital, Budapest, Hungary; Dr A Nicolucci, GIVIO Co-ordinating Centre, Consorzio Mario Negri Sud, Centro Di Ricerchi Farmacologichi, E Biomedichi, Chieta, Italy; Dr U Nylen, Radiumhemmet, Karolinska Sjukhuset, Stockholm, Sweden; Dr T Sahmoud, R Hellmund, AstraZeneca Pharmaceuticals, Wilmington, DE, USA; R Sainsbury, Royal Free and University College Medical School, London, UK; Dr N Griffiths, Dr G Hoctin-Boes, AstraZeneca Pharmaceuticals, Macclesfield, UK; Dr JS Tobias, The Meyerstein Institute of Clinical Oncology, London, UK.
APPENDIX 2: PRINCIPAL AND MAIN INVESTIGATORS IN THE ATAC BONE SUB PROTOCOL
Prof Apffelstaedt, Tyerberg Hospital, Cape Town, South Africa; Dr WW Bate, Mercy Cancer Centre, Mercy Medical Centre, Mason City, IA, USA; Prof Dr Med M Beckmann, Universitat Erlangen-Nurnberg, Erlangen, Germany; Dr MJ Burnell, Atlantic Health Science Group, Saint John, New Brunswick, Canada; Prof A Buzdar, The University of Texas, M.D. Anderson Cancer Center Breast Oncology Clinic Station, Houston, TX, USA; Dr PD Byeff, University of Connecticut, John Dempsey Hospital, Farmington, CT, USA; Dr S Cawthorn, Frenchay Healthcare NHS Trust, Frenchay Hospital, Bristol, UK; Prof R Coleman, Weston Park Hospital, Sheffield, UK; Dr R Coquard, Clinique St Jean, Lyon, France; Dr AC de Boer, Ijsselland Ziekenhuis, Ijssel, Holland; Dr AKR al Debbagh, Trafford General Hospital, Trafford, UK; Dr MA Deutsch, Raleigh Internal Medicine and Wake Haematology/Oncology Clinic, Raleigh, NC, USA; Dr C Dijkhuis, Oosterschelde Ziekenhuis, Goes, Holland; Dr R Fernstad, St Goran's Hospital, Stockholm, Sweden; Dr JP Guestalla, Centre Leon Berard, Lyon, France; Dr D Halkema, Albert Schweitzer Ziekenhuis, Dordrecht, Holland; B Harrison, Northern General Hospital, Sheffield, UK; Dr S Holmberg, SU/Molndal Hospital, Molndal, Sweden; Dr IA Jaiyesimi, Wayne State University School of Medicine, Royal Oak, MI, USA; Dr EP Lester, Oncology Care Associates, PLLC, St Joseph, MI, USA; Dr G Locker, Kellogg Cancer Care Center, Evanston, IL, USA; Dr PA Lyss, Missouri Baptist Cancer Center, St Louis, MO, USA; Dr JR Mackey, Cross Cancer Institute, Edmonton, Alberta, Canada; Prof R Mansel, University Hospital of Wales NHS Trust, Cardiff Breast Unit, Cardiff, UK; Dr U Nylén, Karolinska Sjukhuset, Stockholm, Sweden; Dr P Paterson, Royal Cornwall Hospitals NHS Trust, Treliske Hospital, Truro, UK; Dr KB Pendergrass, Kansas City Oncology and Hematology Group, Lenexa, KS, USA; Dr JG Posada, Division of Haematology/Oncology Scott and White Memorial Hospital, Temple, TX, USA; Dr O Rixe, Hopital Clinique Claude Bernard, Metz, France; Dr J Robert, CHAUQ-Hospital du St-Sacrement, Quebec City, Quebec, Canada; Prof JFR Robertson, Nottingham City Hospital NHS Trust, Nottingham, UK; Dr S Rotstein, Onkologiska Kliniken, Danderyd, Sweden; Dr A Sami, Saskatoon Cancer Centre, University of Saskatchewan Campus, Saskatoon, Saskatchewan, Canada; Dr JI Spector, Berkshire Hematology Oncology, PC, Pittsfield, MA, USA; Dr L Strobbe, Nijmeegs Interconfessioneel, Ziekenhuis Canisius Wilhelmina, Nijmgen, Holland; Dr N Tirumali, Kaiser Permanente/Oncology Research, Portland, OR, USA; Dr A Wardley, Christie Hospital NHS Trust, Manchester, UK.
APPENDIX 3: ADDITIONAL TRIAL COMMITTEES AND COLLABORATIVE/OPERATIONAL GROUPS
International project team
E Foster, SCTN Central Office, Information and Statistics Division, Edinburgh, UK; N Griffiths, A Doe, F Sapunar AstraZeneca Pharmaceuticals, Macclesfield, UK; J Houghton, N Williams, Clinical Trials Group of the Department of Surgery, UCL, London, UK; A Nicolucci, Mario Negri Institute, Chieta, Italy; S Pollard, Northern Yorkshire Clinical Trials Research Unit, Leeds, UK.
Independent data monitoring committee
Dr M Buyse, International Institute for Drug Development (ID squared), Brussels, Belgium; Dr R Margolese, McGill University, The Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada; Prof J J Body, Institute J Bordet, Bruxelles, Belgium.
JF Forbes (group coordinator), JK Wakeham (study coordinator): Australian New Zealand Breast Cancer Trials Group Operations Office, Waratah, Australia; S de Placido (study coordinator), C Carlomagno (study coordinator): Universita Degli Studi Di Napoli Federico II, Naples, Italy; A Nicolucci (group coordinator), M Belfiglio (study coordinator), M Valentini (study coordinator): GIVIO Group, Consorzio Mario Negri Sud, Abruzzi, Italy; E Foster (trial coordinator): Scottish Cancer Therapy Network (SCTN), Information & Statistics Division, Edinburgh, UK; C Lacey (trial monitor): North West Breast Group, Burnley, Lancashire, UK; S Pollard (trial coordinator): Northern & Yorkshire Clinical Trials Research Unit (NCTRU), University of Leeds, Leeds, UK. J Houghton (senior lecturer in clinical trials), N Williams (trial coordinator): Clinical Trials Group of the Department of Surgery, UCL, London, UK. Changes (From Baseline) in Women ≤4 years and >4 Years Since Menopause